What is the likely cause of brief nighttime whole‑body stiffness episodes in a patient taking benztropine 0.5 mg twice daily, escitalopram 10 mg daily, naltrexone 50 mg daily, quetiapine 50 mg at bedtime, and duloxetine delayed‑release 60 mg daily, and how should it be managed?

Brief Nighttime Whole-Body Stiffness: Likely Antidepressant-Induced Sleep Movement Disorder

The most likely cause of this patient's brief (4-5 second) episodes of whole-body stiffness at night is antidepressant-induced sleep movement disorder—specifically hypnic jerks or drug-induced REM sleep behavior disorder (RBD)—triggered by the combination of escitalopram and duloxetine, with quetiapine potentially exacerbating the condition.

Primary Culprits: SSRIs and SNRIs

The patient is taking two serotonergic antidepressants (escitalopram 10 mg and duloxetine 60 mg), both of which have strong evidence for inducing or exacerbating sleep-related movement disorders:

• Escitalopram has the strongest evidence for causing hypnic jerks 1 and drug-induced RLS 2, 3. These are involuntary muscle contractions occurring at sleep onset that match the patient's description of brief whole-body tightening.

• Duloxetine (an SNRI) is documented to cause similar sleep disturbances, though the FDA label 4 does not specifically warn about movement disorders, focusing instead on more common adverse effects like tremor and muscle rigidity.

• The combination of SSRI + SNRI creates additive serotonergic effects that can worsen REM sleep abnormalities 5. Guidelines explicitly state that SSRIs, SNRIs, and tricyclics can induce or exacerbate RBD 5.

Quetiapine's Paradoxical Role

While quetiapine 50 mg at bedtime is often used to treat sleep disturbances, it can paradoxically induce or worsen RLS and periodic limb movements 6, 7. The evidence shows quetiapine-induced movement disorders are frequently misdiagnosed as psychotic agitation 6, but this patient's symptoms are clearly nocturnal and brief, fitting a sleep movement disorder pattern.

The pharmacodynamic interaction between escitalopram and quetiapine can create "phenoconversion" effects even at therapeutic doses 8, potentially amplifying adverse effects beyond what either drug would cause alone.

Why Not Extrapyramidal Symptoms from Quetiapine?

The patient is already on benztropine 0.5 mg BID, an anticholinergic agent used to treat extrapyramidal symptoms (EPS). However:

• The symptoms are exclusively nocturnal and brief (4-5 seconds), which is atypical for EPS
• EPS typically presents as sustained rigidity, not episodic stiffening
• Quetiapine at 50 mg has minimal D2 receptor blockade and rarely causes EPS at this dose 9
• Guidelines actually recommend avoiding benztropine when EPS occurs with antipsychotics 9, as anticholinergics can worsen cognitive function and don't address the root cause

Management Algorithm

Step 1: Confirm the Diagnosis

• Obtain detailed sleep history: timing relative to sleep onset, frequency, associated movements
• Rule out seizures if episodes involve loss of consciousness or post-ictal confusion
• Consider polysomnography if diagnosis remains unclear, though clinical history is usually sufficient 5

Step 2: Medication Adjustment (Choose One Approach)

Option A - Reduce Serotonergic Burden (Preferred):

• Taper and discontinue escitalopram over 10-14 days to avoid withdrawal 4
• Continue duloxetine 60 mg for depression/anxiety coverage
• Monitor for symptom resolution within 2 weeks 2, 1

Option B - If Both Antidepressants Are Essential:

• Add clonazepam 0.25-0.5 mg at bedtime 5, 10, 1
  • Clonazepam is 90% effective for RBD 5 and highly effective for hypnic jerks 1
  • Start low (0.25 mg) due to fall risk and potential cognitive effects
  • Can increase to 0.5-1 mg if needed
• Caution: Clonazepam is on the Beers Criteria list for older adults 10 and can cause morning sedation, falls, and cognitive impairment

Option C - Alternative to Clonazepam:

• Immediate-release melatonin 3-6 mg at bedtime 5, 10
  • Less sedating than clonazepam
  • Fewer drug interactions
  • Can increase by 3 mg increments up to 15 mg if needed
  • Side effects limited to vivid dreams and sleep fragmentation

Step 3: Reassess Benztropine

• Consider tapering benztropine if no clear EPS symptoms exist
• Guidelines explicitly state to avoid benztropine with antipsychotics when possible 9
• Anticholinergics can worsen cognitive function and may paradoxically worsen some movement disorders

Step 4: Monitor Response

• Symptoms should improve within 2 weeks of medication adjustment 2, 1
• If no improvement, reconsider diagnosis and obtain polysomnography
• If symptoms worsen, consider quetiapine as additional contributor and evaluate need for continuation

Critical Pitfalls to Avoid

1. Do not increase benztropine - this will not help sleep movement disorders and may worsen cognition
2. Do not add another antipsychotic - this increases risk of movement disorders
3. Do not ignore the temporal relationship - ask specifically when symptoms started relative to medication initiation
4. Do not assume this is undertreated EPS - the nocturnal, brief nature points to sleep movement disorder, not parkinsonism
5. Do not abruptly stop SSRIs/SNRIs - taper over 10-14 days to minimize discontinuation syndrome 4

Why This Matters for Morbidity and Quality of Life

Sleep movement disorders severely impair sleep quality, leading to:

• Daytime fatigue and functional impairment
• Worsening depression and anxiety
• Increased fall risk if patient gets up during episodes
• Poor medication adherence if symptoms are intolerable 6

The most direct path to symptom resolution is reducing serotonergic medication burden by discontinuing escitalopram, as duloxetine alone provides adequate antidepressant coverage while eliminating the most likely causative agent 2, 1, 3.